The review, authored by Luqi Ying, Zhiwei Zhang, and Luwen Zhao, systematically examines the mechanistic rationale, accumulating clinical evidence, and future directions of combining immune checkpoint inhibitors (ICIs) with poly (ADP-ribose) polymerase inhibitors (PARPis) in ovarian cancer. Its central thesis is that these two drug classes, while developed along entirely separate scientific lineages, attack the disease through distinct yet deeply complementary mechanisms, and that their synergy may be particularly valuable precisely where conventional treatment fails most often: in the setting of acquired platinum resistance.

To appreciate why the combination makes biological sense, it helps to understand why platinum resistance develops in the first place. The authors describe a multifaceted resistance architecture. Tumor cells can ramp up their DNA damage repair machinery, patching the cross-linking lesions that platinum drugs inflict before those lesions become lethal. They can increase drug efflux, pumping chemotherapy out of the cell faster than it accumulates. Perhaps most insidiously, they remodel the tumor immune microenvironment, building an immunosuppressive fortress that shields the malignancy from immune surveillance. Each of these escape routes on its own can doom a single-agent therapy; together, they explain why recurrent platinum-resistant ovarian cancer has proven so stubbornly difficult to treat.

PARP inhibitors were originally designed to exploit a different vulnerability. Poly (ADP-ribose) polymerase is a key enzyme in the repair of single-strand DNA breaks. When PARPis block this enzyme, the unrepaired breaks collapse replication forks and convert into double-strand breaks, which are catastrophic for cells that also lack functional homologous recombination repair, the hallmark of tumors with BRCA mutations or homologous recombination deficiency (HRD). This synthetic lethality principle has already transformed maintenance therapy for ovarian cancer. But the review highlights an emerging second dimension of PARPi activity: beyond directly crippling DNA repair, these drugs fundamentally change how tumors look to the immune system.

The mechanistic centerpiece of the review is the cGAS–STING pathway. When PARPis induce DNA damage, fragments of DNA escape the nucleus and accumulate in the cytoplasm, where the enzyme cyclic GMP-AMP synthase (cGAS) detects them. cGAS activation triggers the stimulator of interferon genes (STING), which sets off a signaling cascade culminating in the production of type I interferons. These interferons act as a molecular alarm, recruiting and activating antigen-presenting cells such as dendritic cells, which then display tumor antigens to cytotoxic T cells. In parallel, PARPi-induced DNA damage can provoke immunogenic cell death, a form of tumor cell demise that releases damage-associated molecular patterns, including calreticulin and high mobility group box 1, which further stoke immune activation. The net effect, as the authors describe it, is the conversion of immunologically cold tumors into hot ones, transforming tumors that were previously invisible to the immune system into inflamed targets teeming with immune activity.

This is where immune checkpoint inhibitors enter the picture. Drugs targeting PD-1 and its ligand PD-L1 release the molecular brakes that tumors place on T cells, but they work only if T cells are present and engaged in the first place. In cold, immunosuppressive tumors, checkpoint blockade alone often achieves little. PARPis solve this problem by generating the very inflammatory context that ICIs require. The combination, in principle, simultaneously ignites the immune response and removes the brakes on it, a logic that the review argues is especially potent against the immunosuppressive milieu that accompanies platinum resistance.

The clinical evidence supporting this paradigm spans multiple disease settings. In the first-line maintenance setting, the DUO-O trial demonstrated that a triple combination of the PD-L1 inhibitor durvalumab, the PARPi olaparib, and bevacizumab significantly extended progression-free survival in patients whose tumors were HRD-positive. This result is notable because it embeds the ICI–PARPi pairing within a broader anti-angiogenic backbone, suggesting that the strategy can deliver measurable benefit even in newly diagnosed disease. In the platinum-resistant recurrent setting, the TOPACIO/KEYNOTE-162 study of pembrolizumab combined with niraparib indicated that response to the combination therapy correlated with DNA repair status, including HRD and BRCA mutation status. Together, these findings suggest that the combination is not a blunt instrument but one whose activity tracks with definable tumor biology.

That last point, biomarker-driven patient selection, emerges as the decisive theme of the review’s forward-looking section. The authors argue that realizing the full potential of personalized treatment in ovarian cancer will require integrating HRD status, features of the immune microenvironment, and emerging predictive factors into a coherent selection framework. Not every patient will benefit from the combination, and the ability to identify responders in advance, through genomic profiling of DNA damage repair defects, assessment of PD-L1 expression or immune infiltration, and potentially novel predictive markers, will determine whether the paradigm fulfills its promise or dissipates into one-size-fits-all disappointment. The review’s extensive abbreviation list, spanning DNA damage response pathways from base excision repair to Fanconi anemia genes, hints at the breadth of molecular features that may eventually inform patient stratification.

Equally important is the unresolved question of resistance. Just as tumors evolved escape routes from platinum chemotherapy, they can be expected to develop mechanisms that blunt the ICI–PARPi combination: loss of antigen presentation, upregulation of alternative checkpoints such as LAG-3 and TIM-3, adaptations in interferon signaling through the JAK–STAT pathway, and further remodeling of the microenvironment by factors such as TGF-β. The authors emphasize that deeper investigation into these resistance mechanisms will be essential, both to anticipate relapse and to design rational next-generation combinations that stack additional agents against parallel escape pathways.

For a disease that has long been defined by grim arithmetic, the convergence of DNA damage biology and cancer immunology offers something genuinely new. The review does not claim victory; it maps a paradigm still under construction, with pivotal trials completed in some settings and open questions in others. But its synthesis makes a compelling case that the future of recurrent platinum-resistant ovarian cancer lies not in any single drug, but in intelligently combined ones, guided by biomarkers that match each patient’s tumor to the therapy most likely to work. If the field can deliver on that vision, one of oncology’s most feared treatment ceilings may finally begin to crack.

Subject of Research: Combination of immune checkpoint inhibitors and PARP inhibitors for recurrent platinum-resistant ovarian cancer

Article Title: A new paradigm for treating recurrent platinum-resistant ovarian cancer: synergistic mechanisms, clinical evidence, and future directions of immune checkpoint inhibitors combined with PARP inhibitors

Article References: Ying, L., Zhang, Z., & Zhao, L. (2026). A new paradigm for treating recurrent platinum-resistant ovarian cancer: synergistic mechanisms, clinical evidence, and future directions of immune checkpoint inhibitors combined with PARP inhibitors. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02270-z

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02270-z

Keywords: ovarian cancer, immune checkpoint inhibitors, PARP inhibitors, platinum resistance, cGAS-STING pathway, homologous recombination deficiency, immunogenic cell death, DUO-O trial, TOPACIO trial, biomarkers, combination therapy, tumor microenvironment